Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathwayBrandon W. Higgs, Zheng Liu, Barbara White et al.|Annals of the Rheumatic Diseases|2011Cited by 412
A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patientsBrandon W. Higgs, Yihong Yao, Wei Zhu et al.|Annals of the Rheumatic Diseases|2013Cited by 168
A novel oncogenic role for the miRNA-506-514 cluster in initiating melanocyte transformation and promoting melanoma growthKatie Streicher, Yandan Yao, Wei Zhu et al.|Oncogene|2011Cited by 135
Micro<scp>RNA</scp>‐206 induces <scp>G</scp>1 arrest in melanoma by inhibition of <scp>CDK</scp>4 and <scp>C</scp>yclin <scp>D</scp>Robert W. Georgantas, Koustubh Ranade, Katie Streicher et al.|Pigment Cell & Melanoma Research|2013Cited by 66
Identification of activated cytokine pathways in the blood of systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma patientsBrandon W. Higgs, Yihong Yao, Wei Zhu et al.|International Journal of Rheumatic Diseases|2011Cited by 60